Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

Gordon J. Freeman, Andrew J. Long, Yoshiko Iwai et al. · The Journal of Experimental Medicine · 2000 · 5.2K citations · Full text

Life Sciences, Immunology, Pathology +17

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

Peter L. Greenberg, Christopher Cox, Michelle M. LeBeau et al. · Blood · 1997 · 4.5K citations · Full text

Medicine, Hematology, Internal Medicine +13

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

Janis M. Taube, Robert A. Anders, Geoffrey D. Young et al. · Science Translational Medicine · 2012 · 2.1K citations

Life Sciences, Immunology, Oncology +14